Ahsan A, Ahmad S, Iqbal O, Schwarz R, Knappenberger G, Joffrion J, Becker JC, Messmore H. Comparative studies on the biochemical and pharmacological properties of a major metabolite of argatroban (MI): potential clinical implications [abstr]. Thromb Haemost 78(suppl 2):370, 1997.

Alsoufi B, Boshkov LK, Kirby A, Ibsen L, Dower N, Shen I, Underlierder R. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 7:155-171, 2004.

Argatroban Prescribing Information. GlaxoSmithKline, Research Triangle Park, April 2002.

Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 355: 809-817, 2006.

Arnold RJ, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. Cardiol Rev 14:7-13, 2006.

Arnoletti JP, Whitman GJR. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann Thorac Surg 68:576-578, 1999.

Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 38:25-29, 2004.

Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 25:157-164, 2005.

Baghdasarian S, Singh I, Militello M, Bartholomew J, Begelman S. Argatroban dosage in critically ill patients with HIT [abstr]. Blood 104:493a, 2004.

Banner DW, Hadvary P. Crystallographic analysis at 3.0-A resolution of the binding to human thrombia of four active site-directed inhibitors. J Biol Chem 266:20085-20093, 1991.

Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 19:179-184, 2005.

Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007; in press.

Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 72:381-386,1994.

Brown PM, Hursting MJ. Lack of pharmacokinetic interactions between argatroban and warfarin. Am J Health Syst Pharm 59:2078-2083, 2002.

Cannon MA, Butterworth J, Riley RD, Hyland JM. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg 77:711-713, 2004.

Clark RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 83:1510-1518,1991.

Cox DS, Kleinman NS, Boyle DA, Aluri J, Parchman LG, Holdbrook F, Fossler MJ. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein Ilb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol 44:981-990, 2004.

Czyz Y, Hoffman WD, Gay S, Hursting MJ. Argatroban therapy for heparin-induced thrombocytopenia after coronary artery bypass graft surgery [abstr]. Am Soc Health-Syst Pharm Midyear Meeting, 2006 (International Pharm Abstracts).

Dager WE, White RH. Argatroban anticoagulation for heparin-induced thrombocyto-penia in hepato-renal failure and CVVHD. Ann Pharmacother 37:1232-1236, 2003.

De Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 37:1237-1240, 2003.

Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 81:36-44, 2006.

Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 75:1622-1624, 2003.

Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin-incidence effects on aPTT and clinical relevance. Blood 96:2373-2378, 2000.

Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 103:613-616, 2004.

Francis JL. Pregnant woman presents with red toe: case study 2. Thrombin Times Newsletter. CME sponsor, University of Kentucky. Publisher, CTI Clinical Trial and Consulting Services. December 15, 7-9, 2004.

Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 16: 251-257, 2005.

Gasparovic H, Nathan NS, Fitzgerald D, Aranki SF. Severe argatroban-induced coagu-lopathy in a patient with history of heparin-induced thrombocytopenia. Ann Thorac Surg 78:e89-e91, 2004.

Gold HK, Torres FW, Garabedian HD, Werner W, Jang I-K, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 21:1039-1047, 1993.

Gorman R, Gordan L, Zumberg M, Kitchens C. Successful use of argatroban as an anticoagulant in burn-related severe acquired antithrombin III deficiency after heparin failure. Thromb Haemost 86:1596-1597, 2001.

Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108:2062-2065, 2003.

Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 22:169-176, 2006.

Hallman SE, Hebbar L, Robison J, Uber WE. The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia. Anesth Analg 100:946-948, 2005.

Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 92:2064-2074,1998.

Harder S, Graff J, Klinkhardt U, von Hentig N, Walenga JM, Watanabe H, Osakabe M, Breddin HK. Transition from argatroban to oral anticoagulation with phenprocou-mon or acenocoumarol: effects on prothrombin time, activated partial thromboplas-tin time, and ecarin clotting time. Thromb Haemost 91:1137-1145, 2004.

Harenberg J, Jorg I, Fenyvesi T, Piazolo L. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J Thromb Thrombolysis 19:65-69, 2005.

Hartman CA, Baroletti SA, Churchill WW, Patel P. Visual compatibility of argatroban with selected drugs. Am J Health Syst Pharm 59:1784-1785, 2002.

Herrman J-P, Suryapranata H, den Heijer P, Gabriel L, Kutryk MJB, Serruys PW. Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J Thromb Thrombolysis 3:367-375,1996.

Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164:361-369, 2004.

Honikso ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health Syst Pharm 61: 2415-2418, 2004.

Hoppensteadt DA, Kahn S, Fareed J. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs. Clin Chem 43: 1786-1788, 1997.

Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol 28:4-10, 2006.

Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 11:279-287, 2005.

Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 45:409-412, 1999.

Ide H, Fujiki T, Sato M, Endo H, Imamura K, Sudo K. Off-pump coronary artery bypass for a heparin-allergic patient. Jpn J Thorac Cardiovasc Surg 49:250-254, 2001.

Iida S, Komatsu T, Sato T, Hayashi K, Inokuchi T. Pharmacokinetic studies of argatroban. (MD-805) in rats: excretion into milk and foeto-placental transfer. Jpn Pharmacol Ther 14:229-235, 1986.

Inglis AML, Sheth SB, Hursting MJ, Tenero DM, Graham AM, DiCicco R. Investigation of the interaction between argatroban and acetaminophen, lidocaine or digoxin. Am J Health Syst Pharm 59:1258-1266, 2002.

Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J. Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost 8:217-224, 2002.

Izawa O, Katsuki M, Komatsu T, Iida S. Pharmacokinetic studies of argatroban (MD-805) in human: concentrations of argatroban and its metabolites in plasma, urine, and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 14: 251-263, 1986.

Jang I-K, Brown DFM, Giugliao RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi S, Massey TJ, Dinsmore R, Schwarz RP, and the MINT investigators. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) trial. J Am Coll Cardiol 33:1879-1885,1999.

Jang I-K, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Throm-bolysis 18:31-37, 2004.

Johnston N, Wait M, Huber L. Argatroban in adult extracorporeal membrane oxygenation. J Extra Corpor Technol 34:281-284, 2002.

Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 14:445-457, 2000.

Kieta DR, McCammon AT, Holman WL, Nielson VG. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 96:956-958, 2003.

Kikumoto R, Tamao Y, Tezeka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Selective inhibition of thrombin by (2R, 4R)-4-methyl-l-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperidinecar-boxylic acid. Biochemistry 23:85-90, 1984.

Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 25:1736-1745, 2005.

Kobayashi W, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 23:531-534, 1997.

Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 21:86-92, 2006.

Koide M, Yamamoto S, Matsuo M, Suzuki S, Arima N, Matsuo T. Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 10:2137-2140,1995.

Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 132:699-700, 2006.

Kumon K, Tanaka K, Nakajima N, Naito Y, Fujita T. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med 12:1039-1043, 1984.

LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, Brown PM. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 35:1677-1682, 2004a.

LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 32:976-980, 2004b.

Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 129:1167-1175, 2006.

Lewis BE, Grassman ED, Wrona L, Rangel Y. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 8:54-58,1997.

Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 49:61-67,1998.

Lewis BE, Wallis DE, Zehnder JL, Barton JC, for the ARG-911/915/915X investigators. Argatroban reexposure in patients with heparin-induced thrombocytopenia [abstr]. Blood 96(Part l):52a, 2000.

Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang I-K, Rifkin SD, Moran J, Hursting MJ, Kelton JG, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838-1843, 2001.

Lewis B, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F, for the ARG-216/ 310/311 investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardio-vasc Interv 57:177-184, 2002.

Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, for the ARG-915 investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849-1856, 2003.

Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129:1407-1416, 2006.

Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3:2428-2436, 2005.

Malherbe S, Tsui B, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmon-ary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 100:443-445, 2004.

Martin ME, Kloecher GH, Patel A, Laber DA. Argatroban for anticoagulation during cardiopulmonary bypass [abstr]. Blood 106:118b, 2005.

Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol 78:161-166, 2007.

Matsuo T, Chikahira Y, Yamada T, Nakao K, Ueshima S, Matsuo O. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 52:165-171, 1988.

Matsuo T, Yamada T, Yamanshi T, Ryo R. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia. Thromb Res 58: 663-666, 1990.

Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: a multi-center clinical trial of argatroban. J Thromb Thrombolysis 2:131-136, 1995.

Matthai WH, Hursting MJ, Lewis BE, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 116: 121-126, 2005.

Mukundan S, Zeigler ZR. Direct antithrombin agents ameliorate disseminated intra-vascular coagulation in suspected heparin-induced thrombocytopenia thrombosis syndrome. Clin Appl Thromb Hemost 8:287-289, 2002.

Murray PT, Reddy BV, Grossman EJ, Hammes MS, Trevino S, Ferrell J, Tang I, Hursting MJ, Shamp TR, Swan SK. A prospective study of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66:2446-2453, 2004.

Nagasawa H, Fukutake K, Hada M, Takahashi E, Natsubara Y, Samori T, Ikematsu S, Kitahara T, Ukita M, Fujimaki M, Fukutake K. Phase one study of synthetic antithrombin agent (MD-805) single and multiple administration studies. Jpn J Clin Pharmacol Ther 12:359-375, 1981.

Nielson VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 25: 653-663, 2006.

Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessels 18: 40-42, 2003.

Okamoto S, Hijikata A. Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereostructure of its hydropho-bic carboxamide portion. Biochem Biophys Res Commun 101:440-446, 1981.

Okamoto S, Okunomiya-Hijikata A. Synthetic selective inhibitors of thrombin. Meth Enzymol 222:328-340, 1993.

Patel K, Hursting MJ. Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration. Am J Health Syst Pharm 62: 1381-1384, 2005.

Pendleton R, Wheeler MM, Rodgers GM. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome. Ann Pharmacother 40:972-976, 2006.

Rawson TE, VanGorp KA, Yang J, Kogan TP. Separation of 2l-(R)- and 2l-(S)-argatro-ban: solubility and activity of the individual diastereoisomers. J Pharm Sci 82: 672-673,1993.

Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 39:1601-1605, 2005.

Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 37:652-654, 2003.

Rice L, Hursting MJ, Baillie GM, McCollum DA. Argatroban anticoagulation in obese versus non-obese patients: implications for treating heparin-induced thrombocyto-penia. J Clin Pharmacol 2007; in press.

Scott LK, Grier LR, Conrad SA. Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal membrane oxygenation managed with argatroban. Pediatr Crit Care Med 7:473-475, 2006.

Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 85:435-440, 2001.

Smythe M, Stephens JL, Koerber JM, Mattson JC. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost 11:371-374, 2005.

Song X, Huhle G, Wang L, Hoffman U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 100:1528-1532,1999.

Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, Mikulik R, Garami Z, Shaw SG, Matherne DE, Moye LA, Alexandrov AV, Grotta JC. Argatro-ban tPA stroke study: study design and results in the first treated cohort. Arch Neurol 63:1057-1062, 2006.

Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20: 318-329, 2000.

Swan SK, St. Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 20: 756-770, 2000.

Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 39:231-236, 2005.

Tatsuno J, Komatsu T, Iida S. Pharmacokinetic studies of argatroban (MD-805): protein binding and blood cell binding. Jpn Pharmacol Ther 14(suppl 5):243-249, 1986.

Theroux P. The Argatroban Myocardial Infarction (AMI) study. Scientific Session News of the American College of Cardiology 15:6, 1997.

Tokuda Y, Matsumoto M, Sugita T, Nishizawa J, Matsuyama K, Yoshida K, Matsuo T. Vascular surgery using argatroban in a patient with history of heparin-induced thrombocytopenia. Circ J 67:889-890, 2003.

Tran JQ, DiCicco RA, Sheth SB, Tucci M, Pend L, Jorkasky DK, Hursting MJ, Benincosa LJ. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 39:513-519, 1999.

Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 37:970-975, 2003.

Vermeer F, Vahanian A, Fels PW, Besse P, Muller E, Van de Werf F, Fitzgerald D, Darius H, Puel J, Garrigou D, Simoons ML for the ARGAMI Study Group. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J Thromb Thrombolysis 10:233-240, 2000.

Walenga JM, Koza MJ, Lewis BE, Pifarre R. Relative heparin-induced thrombocytope-nic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 2(suppl 1):S21-S27,1996.

Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahman S, Wallis DE, Bakhos M. Coagulation laboratory testing patients treated with argatroban. Semin Thromb Hemost 25(suppl 1):61-66, 1999.

Walenga JM, Ahmad S, Hoppensteadt DA, Iqbal O, Hursting MJ, Lewis BE. Argatro-ban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105:401-405, 2002.

Warkentin TE, Greinachaer A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and throm-bolytic therapy. Chest 126 (suppl):311S-337S, 2004.

Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JI, Ofosu FA. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 94:958-964, 2005.

Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacother-apy 24:409-414, 2004.

Yee AJ, Kuter DJ. Successful recovery after an overdose of argatroban. Ann Pharmac-other 40:336-339, 2006.

Young G, Yonekawa KE, Nagakawa P, Nugent DJ. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion 19:283-288, 2004.

Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. Blood Coagul Fibrinolysis 18:97-103, 2007.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment